Keryx Biopharmaceuticals (KERX) Selloff 'Unwarranted'

Article Related Articles (2) Stock Quotes (1) Comments (0)

Last Friday, Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) stock dropped 22 percent. The massive selloff is being tied to $65 million in equity financing announced last week. According the analysts at Oppenheimer, some investors interpreted this as a signal that the company was planning to market Zerenex instead of looking to sell itself. In the view of analysts, this interpretation is not correct and the related selloff is "unwarranted."

"We believe the financing does not prevent an acquisition, and puts the company into a strong negotiating position with a potential partner/acquirer. Furthermore, we believe that this sell-off was unwarranted, and we view the current price as an attractive entry point into the stock," said analyst Boris Peaker.

Peaker said he believes the stock is undervalued without even considering an acquisition premium.

Oppenheimer has an Outperform rating on Keryx Biopharmaceuticals with a price target of $11.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals (NASDAQ: KERX) click here. For more ratings news on Keryx Biopharmaceuticals click here.

Shares of Keryx Biopharmaceuticals closed at $7.11 yesterday, with a 52 week range of $1.28-$9.98.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
• Topeka Capital Starts Atmel (ATML) at Buy
• Topeka Capital Starts Cavium Networks (CAVM) at Hold

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Trader Talk

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?